^
Association details:
| Biomarker: | CD74-ROS1 fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study
Published date:
09/13/2021
Excerpt:
CONTRADICTING EVIDENCE: The overall response rate was 85.7% (144/168) for first-line crizotinib and 41.8% (28/67) for chemotherapy….Patients harboring single CD74-ROS1 (n = 90) had significantly shorter median PFS with crizotinib than those harboring non-CD74 ROS1 fusions (n = 69) (17.0 months vs. 21.0 months; p = 0.008).
DOI:
10.1186/s12916-021-02082-6
Trial ID:
Source:
Title:
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
Excerpt:
...ORR was 70% (95% confidence interval [CI]: 51–85; 21 of 30 patients) and median PFS was 20.0 months (95% CI: 10.1–not reached)....CD74-ROS1-positive patients had a trend towards a higher ORR and longer median PFS....Crizotinib is highly effective and safe in patients with ROS1-rearranged lung cancer.
DOI:
https://doi.org/10.1016/j.jtho.2019.03.020
Trial ID:
Source:
Title:
P46.03-Targeting ROS1 Gene Rearrangement by Crizotinib as Neoadjuvant Treatment Before Definitive Radiotherapy in Locally Advanced NSCLC
Published date:
08/18/2021
Excerpt:
We report a case in an elderly patient with locally advanced ROS1-rearranged NSCLC, in whom Crizotinib was used as neoadjuvant before radiotherapy with curative intent….IHC was negative for ALK and positive for ROS1, and FISH confirmed the ROS1-rearrangement. No mutations in EGFR or other genes were detected by DNA-NGS, while RNA-NGS showed the fusion of ROS1 with CD74 (break-point chr5:149784243, chr6:117645578)....the patient was treated with Crizotinib 250 mg BID with good tolerance and symptoms improvement. PET/CT scan after 5 weeks revealed a partial response both in primary tumor and mediastinal lymph nodes.
